Patent 7202033 was granted and assigned to Sunesis Pharmaceuticals Inc on April, 2007 by the United States Patent and Trademark Office.
The invention concerns the identification of protein kinase inhibitors that preferentially bind to the inactive conformation of a target protein kinase. The inhibitors are identified by locking the target protein kinase in an inactive conformation, and using a covalent tethering approach to identify inhibitors preferentially targeting the inactive conformation.